Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program

PartnershipPositive

AI Analysis

Summary

Assembly Biosciences has exercised its U.S. profit-share option with Gilead for a helicase-primase inhibitor program targeting HSV, indicating progression of the collaborative development effort.

Outcome Details

Assembly Biosciences exercises U.S. profit-share option with Gilead for HSV helicase-primase inhibitor program

Importance:5/10

Sentiment:

0.50

partnershipoption_exerciseantiviralHSVhelicase-primase_inhibitor

Related Companies

$ASMB $GILD

Read the original article

Published by yahoo_finance on September 8, 2026 8:00 PM

Read Original